- Home
- JANX vs DCOM Comparison
JANX vs DCOM Comparison
Compare JANX & DCOM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JANX
- DCOM
- Stock Information
- Founded
- JANX 2017
- DCOM 1864
- Country
- JANX United States
- DCOM United States
- Employees
- JANX N/A
- DCOM N/A
- Industry
- JANX Biotechnology: Pharmaceutical Preparations
- DCOM Major Banks
- Sector
- JANX Health Care
- DCOM Finance
- Exchange
- JANX Nasdaq
- DCOM Nasdaq
- Market Cap
- JANX 1.4B
- DCOM 1.2B
- IPO Year
- JANX 2021
- DCOM 1996
- Fundamental
- Price
- JANX $23.98
- DCOM $30.63
- Analyst Decision
- JANX Strong Buy
- DCOM Strong Buy
- Analyst Count
- JANX 9
- DCOM 3
- Target Price
- JANX $85.00
- DCOM $36.50
- AVG Volume (30 Days)
- JANX 745.4K
- DCOM 180.6K
- Earning Date
- JANX 08-07-2025
- DCOM 10-21-2025
- Dividend Yield
- JANX N/A
- DCOM 3.23%
- EPS Growth
- JANX N/A
- DCOM N/A
- EPS
- JANX N/A
- DCOM 0.87
- Revenue
- JANX $439,000.00
- DCOM $314,165,000.00
- Revenue This Year
- JANX N/A
- DCOM $52.99
- Revenue Next Year
- JANX $591.60
- DCOM $15.71
- P/E Ratio
- JANX N/A
- DCOM $35.43
- Revenue Growth
- JANX N/A
- DCOM N/A
- 52 Week Low
- JANX $21.97
- DCOM $23.25
- 52 Week High
- JANX $71.71
- DCOM $37.60
- Technical
- Relative Strength Index (RSI)
- JANX 49.92
- DCOM 62.10
- Support Level
- JANX $22.41
- DCOM $30.12
- Resistance Level
- JANX $24.00
- DCOM $31.04
- Average True Range (ATR)
- JANX 1.10
- DCOM 0.77
- MACD
- JANX 0.01
- DCOM 0.09
- Stochastic Oscillator
- JANX 42.20
- DCOM 80.12
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
About DCOM Dime Community Bancshares Inc.
Dime Community Bancshares Inc operates as a holding company. It gathers deposits from customers within its market area and via the internet and invests them in multifamily residential, commercial real estate, commercial and industrial (C&I) loans, and one-to-four family residential real estate loans, as well as mortgage-backed securities, obligations of the U.S. government and government- sponsored enterprises (GSEs), and corporate debt and equity securities. The company has one reportable segment which is Community Banking.